Equillium (NASDAQ:EQ) Releases Earnings Results, Beats Estimates By $0.01 EPS

Posted by George Bondi on Aug 13th, 2026

Equillium (NASDAQ:EQ – Get Free Report) issued its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, FiscalAI reports.

Equillium Trading Down 7.8%

Shares of NASDAQ EQ traded down $0.17 during mid-day trading on Thursday, reaching $2.01. 542,877 shares of the company’s stock were exchanged, compared to its average volume of 503,391. Equillium has a 52 week low of $0.76 and a 52 week high of $3.54. The firm has a 50-day moving average price of $2.69 and a two-hundred day moving average price of $2.22.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on EQ shares. Roth Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Equillium in a report on Thursday, May 28th. Piper Sandler initiated coverage on Equillium in a report on Monday, July 13th. They set an “overweight” rating for the company. Stifel Nicolaus set a $5.00 price objective on Equillium in a research note on Thursday, May 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Equillium in a research report on Wednesday, June 24th. Finally, Zacks Research raised Equillium from a “strong sell” rating to a “hold” rating in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Equillium presently has an average rating of “Moderate Buy” and an average target price of $7.57.

View Our Latest Analysis on EQ

Insider Activity at Equillium

In other Equillium news, COO Christine Zedelmayer sold 86,012 shares of Equillium stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $2.80, for a total value of $240,833.60. Following the sale, the chief operating officer owned 62,586 shares of the company’s stock, valued at approximately $175,240.80. The trade was a 57.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Penny Tom sold 65,000 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $2.95, for a total transaction of $191,750.00. Following the transaction, the insider directly owned 65,000 shares of the company’s stock, valued at $191,750. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 406,392 shares of company stock worth $1,224,898. 17.84% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Virtu Financial LLC grew its stake in Equillium by 133.4% in the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock valued at $34,000 after buying an additional 13,591 shares in the last quarter. State Street Corp raised its holdings in Equillium by 13.0% during the 4th quarter. State Street Corp now owns 155,420 shares of the company’s stock valued at $241,000 after acquiring an additional 17,900 shares during the period. Persistent Asset Partners Ltd lifted its position in shares of Equillium by 35.0% during the fourth quarter. Persistent Asset Partners Ltd now owns 93,123 shares of the company’s stock worth $144,000 after acquiring an additional 24,132 shares in the last quarter. Millennium Management LLC purchased a new stake in shares of Equillium during the third quarter worth $35,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Equillium by 11.1% in the fourth quarter. Geode Capital Management LLC now owns 345,310 shares of the company’s stock worth $535,000 after acquiring an additional 34,491 shares during the period. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

(Get Free Report)

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.